
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 24, 2024

MOLINA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

1-31719
(Commission File Number)

13-4204626
(IRS Employer Identification No.)

200 Oceangate, Suite 100, Long Beach, California
(Address of principal executive offices)

90802
(Zip Code)

Registrant's telephone number, including area code: (562) 435-3666

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 Par Value	MOH	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On July 24, 2024, Molina Healthcare, Inc. (the “Company”) issued a press release reporting its financial results for the second quarter ended June 30, 2024 and reaffirming the Company’s full-year 2024 revenue and earnings guidance. The full text of the press release is included as Exhibit 99.1 to this report. The information contained in the Company’s website cited in the press release is not part of this report.

Note: The information in this Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.	Description
99.1	Press release of Molina Healthcare, Inc., issued July 24, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MOLINA HEALTHCARE, INC.

Date: July 24, 2024

By: /s/ Jeff D. Barlow
Jeff D. Barlow
Chief Legal Officer and Secretary

News Release

Investor Contact: Jeffrey Geyer, Jeffrey.Geyer@molinahealthcare.com, 305-317-3012

Media Contact: Caroline Zubieta, Caroline.Zubieta@molinahealthcare.com, 562-951-1588

Molina Healthcare Reports Second Quarter 2024 Financial Results
Reaffirms Full Year 2024 Earnings Guidance

Long Beach, Calif, July 24, 2024 – Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported second quarter 2024 GAAP earnings per diluted share of \$5.17 and adjusted earnings per diluted share of \$5.86. Financial results are summarized below:

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
<i>(In millions, except per-share results)</i>				
Premium Revenue	\$9,446	\$8,042	\$18,950	\$15,927
Total Revenue	\$9,880	\$8,327	\$19,811	\$16,476
GAAP:				
Net Income	\$301	\$309	\$602	\$630
EPS – Diluted	\$5.17	\$5.35	\$10.33	\$10.87
Medical Care Ratio (MCR)	88.6 %	87.5 %	88.6 %	87.3 %
G&A Ratio	7.0 %	7.4 %	7.1 %	7.3 %
After-tax Margin	3.0 %	3.7 %	3.0 %	3.8 %
Adjusted:				
Net Income	\$341	\$327	\$675	\$664
EPS – Diluted	\$5.86	\$5.65	\$11.59	\$11.45
G&A Ratio	6.9 %	7.4 %	7.0 %	7.3 %
After-tax Margin	3.5 %	3.9 %	3.4 %	4.0 %

See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.

Quarter Highlights

- As of June 30, 2024, the Company served approximately 5.6 million members, an increase of 8% compared to June 30, 2023.
- Premium revenue was approximately \$9.4 billion for the second quarter of 2024, an increase of 17% year over year.
- GAAP net income was \$5.17 per diluted share for the second quarter of 2024, a decrease of 3% year over year.
- Adjusted net income was \$5.86 per diluted share for the second quarter of 2024, an increase of 4% year over year.
- The Company reaffirmed its full year 2024 guidance with expected premium revenue of approximately \$38 billion and adjusted earnings of at least \$23.50 per diluted share.

-MORE-

“We are pleased with our performance in the quarter as our flagship Medicaid business continues to perform well along with strong contributions from both our Medicare and Marketplace businesses,” said Joseph Zubretsky, President and Chief Executive Officer. “We have successfully navigated the unprecedented redetermination process, and these highly attractive businesses provide the foundation for near and long-term sustainable profitable growth.”

Premium Revenue

Premium revenue was approximately \$9.4 billion for the second quarter of 2024, an increase of 17% year over year. The higher premium revenue reflects new contract wins, acquisitions, and growth in our current footprint, partially offset by the impact of Medicaid redeterminations.

Net Income

GAAP net income for the second quarter of 2024 was \$5.17 per diluted share, a decrease of 3% year over year. Adjusted net income for the second quarter of 2024 was \$5.86 per diluted share, an increase of 4% year over year.

Medical Care Ratio (MCR)

- The consolidated MCR for the second quarter of 2024 was 88.6% and reflects continued focus on managing medical costs.
- The Medicaid MCR for the second quarter of 2024 was 90.8%. Within that result, approximately 70 basis points were due to a one-time, retroactive premium adjustment related to the prior year. “New store” Medicaid plans increased the reported MCR by approximately 80 basis points. Excluding the one-time item and new stores, the Medicaid MCR was approximately 89.3% and modestly higher than the Company’s long-term expectations due to redetermination-related acuity shifts.
- The Medicare MCR for the second quarter of 2024 was 84.9%, better than the Company’s expectations, and reflects favorable risk adjustment results, and benefit adjustments implemented for 2024.
- The Marketplace MCR for the second quarter of 2024 was 71.6%, better than the Company’s expectations, and reflects the Company’s favorable risk adjustment results.

General and Administrative Expense Ratio

The G&A ratio and the adjusted G&A ratio for the second quarter of 2024 were 7.0% and 6.9%, respectively.

Balance Sheet

Cash and investments at the parent company were \$235 million as of June 30, 2024 compared to \$742 million as of December 31, 2023.

Days in claims payable at June 30, 2024 was 50.

Cash Flow

Operating cash flow for the six months ended June 30, 2024 was a use of \$5 million, compared to \$1,403 million for the six months ended June 30, 2023. The decrease in cash flow for the period year-over-year was driven mainly by the net impact of timing differences in government receivables and payables, including Medicare and Medicaid prepayments, risk corridor settlement activity, and timing differences in receipts and payments of provider payables.

-MORE-

2024 Guidance

Premium revenue for the full year is expected to be approximately \$38 billion, an increase of approximately 17% from the full year 2023.

The Company reaffirms its full year adjusted earnings per diluted share in 2024 to be at least \$23.50, representing approximately 13% growth over the full year 2023. The Medicaid pressure experienced in the second quarter of 2024 is expected to be offset by higher net investment income and the extension of Virginia and Florida contracts in the second half of the year. The Company's known rate adjustments in the second half of the year are expected to largely offset higher expected trend in the second half of the year.

Conference Call

Management will host a conference call and webcast to discuss Molina Healthcare's second quarter results at 8:00 a.m. Eastern Time on Thursday, July 25, 2024. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 8508329. A telephonic replay of the conference call will be available through Thursday, August 1, 2024, by dialing (877) 344-7529 and entering confirmation number 5266367. A live audio broadcast of this conference call will be available on Molina Healthcare's website, [molinahealthcare.com](https://www.molinahealthcare.com). A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit [molinahealthcare.com](https://www.molinahealthcare.com).

-MORE-

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This earnings release and the Company's accompanying oral remarks contain forward-looking statements. The Company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this earnings release and the Company's accompanying oral remarks may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as "guidance," "future," "anticipates," "believes," "embedded," "estimates," "expects," "growth," "intends," "plans," "predicts," "projects," "will," "would," "could," "can," "may," or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding our business and financial performance, 2024 guidance and long-term targets, expected headwinds, normal and off-cycle Medicaid rate adjustments, and management's plans and objectives for future operations and business strategy.

Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings "Forward-Looking Statements," and "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which is on file with the U.S. Securities and Exchange Commission (the "SEC"), and in the Company's other filings with the SEC, including its Quarterly Report on Form 10-Q for the period ended June 30, 2024, to be filed with the SEC.

These reports can be accessed under the investor relations tab of the Company's website or on the SEC's website at [sec.gov](https://www.sec.gov). Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company's judgment as of July 24, 2024, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.

-MORE-

MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
<i>(In millions, except per-share amounts)</i>				
Revenue:				
Premium revenue	\$ 9,446	\$ 8,042	\$ 18,950	\$ 15,927
Premium tax revenue	298	169	595	341
Investment income	115	97	223	168
Other revenue	21	19	43	40
Total revenue	<u>9,880</u>	<u>8,327</u>	<u>19,811</u>	<u>16,476</u>
Operating expenses:				
Medical care costs	8,368	7,038	16,782	13,909
General and administrative expenses	691	618	1,402	1,209
Premium tax expenses	298	169	595	341
Depreciation and amortization	46	42	91	86
Other	43	17	81	33
Total operating expenses	<u>9,446</u>	<u>7,884</u>	<u>18,951</u>	<u>15,578</u>
Operating income	434	443	860	898
Interest expense	28	27	55	55
Income before income tax expense	406	416	805	843
Income tax expense	105	107	203	213
Net income	<u>\$ 301</u>	<u>\$ 309</u>	<u>\$ 602</u>	<u>\$ 630</u>
Net income per share – Diluted	<u>\$ 5.17</u>	<u>\$ 5.35</u>	<u>\$ 10.33</u>	<u>\$ 10.87</u>
Diluted weighted average shares outstanding	<u>58.2</u>	<u>57.9</u>	<u>58.3</u>	<u>58.0</u>

-MORE-

**MOLINA HEALTHCARE, INC.
CONSOLIDATED BALANCE SHEETS**

	June 30, 2024	December 31, 2023
	Unaudited	
	<i>(Dollars in millions, except per-share amounts)</i>	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 4,354	\$ 4,848
Investments	4,347	4,259
Receivables	3,231	3,104
Prepaid expenses and other current assets	399	331
Total current assets	12,331	12,542
Property, equipment, and capitalized software, net	305	270
Goodwill and intangible assets, net	1,913	1,449
Restricted investments	268	261
Deferred income taxes, net	232	227
Other assets	136	143
Total assets	\$ 15,185	\$ 14,892
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Medical claims and benefits payable	\$ 4,577	\$ 4,204
Amounts due government agencies	2,273	2,294
Accounts payable, accrued liabilities and other	973	1,252
Deferred revenue	13	418
Total current liabilities	7,836	8,168
Long-term debt	2,181	2,180
Finance lease liabilities	203	205
Other long-term liabilities	122	124
Total liabilities	10,342	10,677
Stockholders' equity:		
Common stock, \$0.001 par value, 150 million shares authorized; outstanding: 59 million shares at June 30, 2024, and 58 million at December 31, 2023	—	—
Preferred stock, \$0.001 par value; 20 million shares authorized, no shares issued and outstanding	—	—
Additional paid-in capital	439	410
Accumulated other comprehensive loss	(85)	(82)
Retained earnings	4,489	3,887
Total stockholders' equity	4,843	4,215
Total liabilities and stockholders' equity	\$ 15,185	\$ 14,892

-MORE-

MOLINA HEALTHCARE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six Months Ended	
	June 30,	
	2024	2023
	<i>(In millions)</i>	
Operating activities:		
Net income	\$ 602	\$ 630
Adjustments to reconcile net income to net cash (used in) provided by operating activities:		
Depreciation and amortization	91	86
Deferred income taxes	21	(4)
Share-based compensation	68	55
Other, net	4	5
Changes in operating assets and liabilities:		
Receivables	(5)	(83)
Prepaid expenses and other current assets	16	6
Medical claims and benefits payable	(48)	149
Amounts due government agencies	(43)	510
Accounts payable, accrued liabilities and other	(307)	(208)
Deferred revenue	(405)	55
Income taxes	1	202
Net cash (used in) provided by operating activities	(5)	1,403
Investing activities:		
Purchases of investments	(594)	(924)
Proceeds from sales and maturities of investments	506	546
Net cash paid in business combinations	(295)	—
Purchases of property, equipment, and capitalized software	(54)	(63)
Other, net	2	2
Net cash used in investing activities	(435)	(439)
Financing activities:		
Common stock withheld to settle employee tax obligations	(56)	(59)
Other, net	6	4
Net cash used in financing activities	(50)	(55)
Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents	(490)	909
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period	4,908	4,048
Cash, cash equivalents, and restricted cash and cash equivalents at end of period	\$ 4,418	\$ 4,957

-MORE-

MOLINA HEALTHCARE, INC.
UNAUDITED SEGMENT DATA
(Dollars in millions)

	June 30, 2024	December 31, 2023	June 30, 2023
Ending Membership by Segment:			
Medicaid	4,942,000	4,542,000	4,741,000
Medicare	251,000	172,000	166,000
Marketplace	386,000	281,000	269,000
Total	<u>5,579,000</u>	<u>4,995,000</u>	<u>5,176,000</u>

Three Months Ended June 30,

	2024			2023		
	Premium Revenue	Medical Margin	MCR ⁽¹⁾	Premium Revenue	Medical Margin	MCR ⁽¹⁾
Medicaid	\$ 7,378	\$ 683	90.8 %	\$ 6,485	\$ 756	88.3 %
Medicare	1,441	217	84.9	1,044	113	89.2
Marketplace	627	178	71.6	513	135	73.7
Consolidated	<u>\$ 9,446</u>	<u>\$ 1,078</u>	88.6 %	<u>\$ 8,042</u>	<u>\$ 1,004</u>	87.5 %

Six Months Ended June 30,

	2024			2023		
	Premium Revenue	Medical Margin	MCR ⁽¹⁾	Premium Revenue	Medical Margin	MCR ⁽¹⁾
Medicaid	\$ 14,870	\$ 1,458	90.2 %	\$ 12,834	\$ 1,490	88.4 %
Medicare	2,883	380	86.8	2,090	239	88.6
Marketplace	1,197	330	72.4	1,003	289	71.2
Consolidated	<u>\$ 18,950</u>	<u>\$ 2,168</u>	88.6 %	<u>\$ 15,927</u>	<u>\$ 2,018</u>	87.3 %

(1) The MCR represents medical costs as a percentage of premium revenue.

-MORE-

MOLINA HEALTHCARE, INC.
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)

The Company's claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company's reserving methodology is consistently applied across all periods presented. The amounts displayed for "Components of medical care costs related to: Prior year" represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:

	Six Months Ended	
	June 30,	
	2024	2023
	Unaudited	
Medical claims and benefits payable, beginning balance	\$ 4,204	\$ 3,528
Components of medical care costs related to:		
Current year	17,301	14,180
Prior year	(519)	(271)
Total medical care costs	16,782	13,909
Payments for medical care costs related to:		
Current year	13,429	11,166
Prior year	3,161	2,650
Total paid	16,590	13,816
Acquired balances, net of post-acquisition adjustments	421	—
Change in non-risk and other payables	(240)	56
Medical claims and benefits payable, ending balance	\$ 4,577	\$ 3,677
Days in Claims Payable ⁽¹⁾	50	47

(1) The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company's consolidated financial statements.

-MORE-

MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)

The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company's performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company's performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.

Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.

Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.

Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company's financial performance.

Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.

Adjusted after-tax margin represents adjusted net income, divided by total revenue.

	Three Months Ended June 30,				Six Months Ended June 30,			
	2024		2023		2024		2023	
	Amount	Per Diluted Share	Amount	Per Diluted Share	Amount	Per Diluted Share	Amount	Per Diluted Share
GAAP Net income	\$ 301	\$ 5.17	\$ 309	\$ 5.35	\$ 602	\$ 10.33	\$ 630	\$ 10.87
Adjustments:								
Amortization of intangible assets	\$ 21	\$ 0.36	\$ 22	\$ 0.36	\$ 41	\$ 0.71	\$ 43	\$ 0.73
Acquisition-related expenses ⁽¹⁾	18	0.31	2	0.03	35	0.60	2	0.03
Other ⁽²⁾	14	0.24	—	—	20	0.35	—	—
Subtotal, adjustments	53	0.91	24	0.39	96	1.66	45	0.76
Income tax effect	(13)	(0.22)	(6)	(0.09)	(23)	(0.40)	(11)	(0.18)
Adjustments, net of tax	40	0.69	18	0.30	73	1.26	34	0.58
Adjusted net income	\$ 341	\$ 5.86	\$ 327	\$ 5.65	\$ 675	\$ 11.59	\$ 664	\$ 11.45

(1) Reflects non-recurring costs associated with acquisitions, including various transaction and certain integration costs.

(2) The six months ended June 30, 2024 includes non-recurring litigation costs and one-time termination benefits.

-MORE-

MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)
2024 GUIDANCE

	Amount	Per Diluted Share ⁽²⁾
GAAP Net income	\$ 1,256	\$ 21.62
Adjustments:		
Amortization of intangible assets	83	1.42
Acquisition-related expenses	44	0.75
Other	20	0.35
Subtotal, adjustments	147	2.52
Income tax effect ⁽¹⁾	(38)	(0.64)
Adjustments, net of tax	109	1.88
Adjusted net income	\$ 1,365	\$ 23.50

(1) Income tax effect calculated at the statutory tax rate of approximately 23.9%.

(2) Computations assume approximately 58.1 million diluted weighted average shares outstanding.

-END-